{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:51:43Z","timestamp":1781153503741,"version":"3.54.1"},"reference-count":41,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic associated fatty liver disease (MAFLD) is the most common chronic liver disease, with an estimated prevalence of between 20 and 30% worldwide. Observational data supported by in vitro and pre-clinical animal models of MAFLD suggest meaningful differences in drug disposition in MAFLD patients. This study aimed to build a physiologically based pharmacokinetic (PBPK) model reflecting observed changes in physiological and molecular parameters relevant to drug disposition that are associated with MAFLD. A comprehensive literature review and meta-analysis was conducted to identify all studies describing in vivo physiological changes along with in vitro and pre-clinical model changes in CYP 1A2, 2C9, 2C19, 2D6 and 3A4 protein abundance associated with MAFLD. A MAFLD population profile was constructed in Simcyp (version 19.1) by adapting demographic and physiological covariates from the Sim-Healthy population profile based on a meta-analysis of observed data from the published literature. Simulations demonstrated that single dose and steady state area under the plasma concentration time curve (AUC) for caffeine, clozapine, omeprazole, metoprolol, dextromethorphan and midazolam, but not s-warfarin or rosiglitazone, were increased by &gt;20% in the MAFLD population compared to the healthy control population. These findings indicate that MAFLD patients are likely to be experience meaningfully higher exposure to drugs that are primarily metabolized by CYP 1A2, 2C19, 2D6 and 3A4, but not CYP2C9. Closer monitoring of MAFLD patients using drugs primarily cleared by CYP 1A2, 2C19 and 3A4 is warranted as reduced metabolic activity and increased drug exposure are likely to result in an increased incidence of toxicity in this population.<\/jats:p>","DOI":"10.3390\/ijms231911751","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:39:31Z","timestamp":1665272371000},"page":"11751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure"],"prefix":"10.3390","volume":"23","author":[{"given":"Elise M.","family":"Newman","sequence":"first","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-3954","authenticated-orcid":false,"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia"},{"name":"Beat Cancer Fellow, Cancer Council South Australia, Adelaide 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2018.06.029","article-title":"Human-based systems: Mechanistic NASH modelling just around the corner?","volume":"134","author":"Boeckmans","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/apt.12046","article-title":"Review article: Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?","volume":"36","author":"Yilmaz","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019\u20132030","volume":"35","author":"Adams","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Newman, L.A., Sorich, M.J., and Rowland, A. (2020). Role of extracellular vesicles in the pathophysiology, diagnosis and tracking of non-alcoholic fatty liver disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072032"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort","volume":"70","author":"Simon","year":"2020","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic Fatty Liver Disease and Recent Guideline Updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clinical Liver Disease."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(02)11203-7","article-title":"Clinical importance of cytochromes P450","volume":"360","author":"Nebert","year":"2002","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e21840","DOI":"10.1002\/jbt.21840","article-title":"In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice","volume":"31","author":"Li","year":"2017","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1515\/dmpt-2016-0008","article-title":"Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease","volume":"31","author":"Kulkarni","year":"2016","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18433\/jpps30268","article-title":"Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats","volume":"22","author":"Bang","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/00498254.2020.1851070","article-title":"Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid","volume":"51","author":"Li","year":"2021","journal-title":"Xenobiotica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: Report of an FDA public workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1002\/jcph.1767","article-title":"Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018\u20132019 Submissions to the US FDA\u2019s Office of Clinical Pharmacology","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/psp4.12166","article-title":"Report from the EMA Workshop on Qualification and Reporting of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation","volume":"6","author":"Zhao","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S1600","DOI":"10.21037\/tcr.2017.10.16","article-title":"Physiologically-based pharmacokinetic modeling as an approach to evaluate the effect of covariates and drug-drug interactions on variability in epidermal growth factor receptor kinase inhibitor exposure","volume":"6","author":"Rowland","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cpdd.638","article-title":"Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development","volume":"8","author":"Polasek","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic Cyotchrome P450 (CYP) 3A4 induction and de-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/jgh.12580","article-title":"Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver","volume":"29","author":"Jiang","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MEG.0000000000000015","article-title":"Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis","volume":"26","author":"Li","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/hepr.12384","article-title":"Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease","volume":"45","author":"Shima","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Le, M., Devaki, P., Ha, N.B., Jun, D.W., Te, H.S., Cheung, R.C., and Nguyen, M.H. (2017). Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173499"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1124\/dmd.106.009670","article-title":"Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts","volume":"34","author":"Donato","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.tiv.2006.07.008","article-title":"Effects of steatosis on drug-metabolizing capability of primary human hepatocytes","volume":"21","author":"Donato","year":"2007","journal-title":"Toxicol. Vitr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2006.12.021","article-title":"Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity","volume":"5","author":"Kolwankar","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"Cytochrome P450 3A Activity and Expression in Non-Alcoholic Fatty Liver Disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jamwal, R., and Barlock, B.J. (2020). Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090222"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Murphy, W.A., Adiwidjaja, J., Sj\u00f6stedt, N., Yang, K., Beaudoin, J.J., Spires, J., Siler, S.Q., Neuhoff, S., and Brouwer, K.L. (2022, July 20). Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Available online: https:\/\/www.webofscience.com\/wos\/woscc\/full-record\/WOS:000804990500001.","DOI":"10.1002\/cpt.2614"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.117.079624","article-title":"Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease","volume":"46","author":"Tirona","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","first-page":"661","article-title":"Guidelines for bioavailability and bioequivalence studies: A review","volume":"7","author":"Aruna","year":"2018","journal-title":"Pharma Innov. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.16489","article-title":"Review article: Time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment","volume":"54","author":"Darwich","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.252049","article-title":"Organic Anion Transporter 2 mediated Hepatic Uptake Contribute to the Clearance of High Permeability\u2014Low Molecular Weight Acid and Zwitterion Drugs: Evaluation using 25 drugs","volume":"367","author":"Kimoto","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp\u00ae Population-based ADME Simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert. Opin. Drug Metab. Toxicol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:46:14Z","timestamp":1760143574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":41,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911751"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911751","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}